Ipsen moved to expand its myelofibrosis franchise with an agreement to acquire Kartos Therapeutics for $450 million upfront, alongside potential milestones up to $1.75 billion. The purchase centers on navtemadlin, an oral MDM2 inhibitor designed to reactivate p53 in patients who experience suboptimal responses to JAK therapy. Ipsen is positioning navtemadlin as a potential add-on and alternative route for the significant patient population that discontinues or fails Jakafi due to imperfect efficacy. Kartos’ phase 1b/2 data supporting the add-on concept include spleen-volume and symptom improvements in a small subgroup of patients previously exposed to Jakafi. The combined program load includes an ongoing phase 3 trial targeting intermediate- and high-risk TP53 myelofibrosis patients with prior suboptimal response to Jakafi, with a topline readout expected next year. Net-net, the deal shows continued pharma push toward mechanism-based p53 pathway reactivation to complement JAK inhibition in myelofibrosis, with Ipsen explicitly betting on a differentiated clinical pathway and later-stage execution.